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AbstrACt
The scientific basis for antenatal corticosteroids (ACS) for 
women at risk of preterm birth has rapidly changed in recent 
years. Two landmark trials—the Antenatal Corticosteroid 
Trial and the Antenatal Late Preterm Steroids Trial—have 
challenged the long-held assumptions on the comparative 
health benefits and harms regarding the use of ACS for 
preterm birth across all levels of care and contexts, including 
resource-limited settings. Researchers, clinicians, programme 
managers, policymakers and donors working in low-income 
and middle-income countries now face challenging questions 
of whether, where and how ACS can be used to optimise 
outcomes for both women and preterm newborns.
In this article, we briefly present an appraisal of the current 
evidence around ACS, how these findings informed WHO’s 
current recommendations on ACS use, and the knowledge 
gaps that have emerged in the light of new trial evidence. 
Critical considerations in the generalisability of the 
available evidence demonstrate that a true state of clinical 
equipoise exists for this treatment option in low-resource 
settings. An expert group convened by WHO concluded that 
there is a clear need for more efficacy trials of ACS in these 
settings to inform clinical practice.
tHe globAl burden And risks of preterm 
birtH
Preterm birth is defined as live births occurring 
before 37 completed weeks of gestation.1 An esti-
mated 14.9 million neonates were born preterm 
in 2010, accounting for 11.1% of live births world-
wide.2 The majority of all preterm births occur in 
the late preterm period (34 to <37 weeks)—for 
example, in the USA more than 70% of preterm 
births in 2014 were born in the late preterm 
period.3 It is estimated that more than 60% of 
the world’s preterm births occur in sub-Saharan 
African and South Asian countries.2
Prematurity can be a lethal condition, 
particularly for those newborns born at 
earlier gestational ages. Complications of 
Key messages 
What is already known about this topic?
 ► Antenatal corticosteroids (ACS) have been 
considered the gold standard treatment for reducing 
preterm-associated neonatal morbidity and mortality 
for decades. However, the unexpected findings of the 
recently published Antenatal Corticosteroids Trial in 
low-income and middle-income countries (LMICs) 
have challenged long-held assumptions on the 
comparative health benefits and harms of ACS use 
in LMICs across of all levels of care.
 ► In 2015, WHO recommended ACS use up to 34 
weeks’ gestation with strict treatment criteria to 
guide its use, in acknowledgement of unanswered 
questions about safety and efficacy in hospitals in 
low-resource countries.
new information
 ► A reappraisal of the hallmark Cochrane review 
evidence identified several limitations that 
undermine generalisability to lower-income 
countries. Furthermore, the recent Antenatal Late 
Preterm Steroids trial conducted in tertiary centres 
in the USA reported some benefits for late preterm 
newborns. Questions still remain regarding the 
applicability of this new evidence to hospitals in low-
resource countries.
 ► WHO convened an expert group that reviewed the 
available evidence—the group agreed that efficacy 
trials on ACS use for preterm birth in hospitals in low-
resource countries are justified, to guide clinicians 
and policymakers on whether, how and where ACS 
can be used safely and effectively in these settings.
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preterm birth are the leading cause of death in children 
under 5 years of age globally, accounting for 1.06 million 
deaths (uncertainty range 0.935 to 1.179 million) of the 
5.9 million deaths estimated to have occurred in 2015.4 
Those preterm neonates who survive are at increased 
risk of a wide range of respiratory, infectious, metabolic 
and neurological morbidities. Preterm infants expe-
rience higher rates of respiratory distress syndrome, 
bronchopulmonary dysplasia, necrotising enterocolitis, 
kernicterus, hypoglycaemia, periventricular leucoma-
lacia, seizures, intraventricular haemorrhage, cerebral 
palsy, infections, feeding difficulties, hypoxic ischaemic 
encephalopathy, retinopathy of prematurity, as well as 
visual and hearing loss.5–16 Preterm birth and its sequelae 
can have significant negative psychosocial and financial 
impacts on families of preterm newborns.17–20
While the risks of mortality and morbidity affecting 
preterm newborns are considerably more frequent at 
lower gestational ages,11 late preterm infants (some-
times called ‘near-term’) still experience significantly 
higher risks compared with babies born at term.21 
A systematic review of more than 29 million infants 
(mostly in high-income countries) found that, 
compared with term birth, late preterm birth was asso-
ciated with increased 28-day mortality (Risk Ratio (RR) 
5.9, 95% CI 5.0 to 6.9) and 1-year mortality (RR 3.7, 
95% CI 2.9 to 4.6).21
AntenAtAl CortiCosteroids
Antenatal corticosteroids (ACS) have long been 
regarded as a cornerstone intervention in mitigating 
the adverse effects of preterm birth. The Cochrane 
Collaboration logo is itself constructed from an early 
ACS meta-analysis.22 The first randomised controlled 
trial of ACS (betamethasone) in humans to prevent 
respiratory distress syndrome was published in 1972.23 
Since then, dozens more trials have been conducted, 
exploring neonatal risks and benefits when given to 
women at risk of preterm birth,24 the use of different 
dosing regimens25 and the use of ACS for preventing 
neonatal respiratory morbidity after elective caesarean 
section at term.26
In March 2017, the updated Cochrane systematic review 
on ACS for accelerating fetal lung maturation for women 
at risk of preterm birth was published, including 30 trials 
of 7774 women and 8158 infants.27 The findings are 
similar to earlier iterations, showing striking reductions 
in neonatal mortality and several morbidity outcomes 
(box 1). This analysis has contributed to the widespread 
(and often overly liberal) use of ACS for women at risk 
of preterm birth, including in low-income and middle-in-
come countries (LMICs).28
However, there are several critical limitations in the 
Cochrane review evidence base that complicate their 
application to many hospitals in LMICs, as discussed 
below.
A reApprAisAl of tHe CoCHrAne revieW evidenCe
trial settings
The 30 trials were conducted in higher-level hospital 
settings, in high-income (20 trials) and upper middle-in-
come (nine trials) countries, except one trial that was 
conducted in Tunisia (a lower middle income country).29 
It seems reasonable to assume that the level of maternal 
and newborn care provided reflected the best available at 
the time the studies were conducted, including the accu-
racy of gestational age estimation for recruited women. 
Comparatively, no placebo-controlled efficacy trials of 
ACS have been conducted in low-income countries, 
where the rates of maternal and newborn mortality and 
morbidity are higher, and the level of health and human 
resources available to manage pregnant women and 
preterm infants substantially lower. Despite this, ACS are 
routinely used in facilities in many lower-income coun-
tries.30
Age of the trials and risk of bias
The Antenatal Late Preterm Steroid (ALPS) Trial 
published in 201631 (discussed further below) is the 
largest trial in this meta-analysis. Among the other 29 
trials, three-quarters of participants were randomised 
more than 20 years ago. While the age of a trial itself is 
not necessarily an indication of poor quality, reports of 
older trials often contain no or insufficient information 
to fully assess their risk of bias. Importantly, the context 
of maternal and newborn care has changed substantially 
since those trials were conducted—interventions such 
as oxygen therapy, continuous positive airway pressure 
(CPAP), thermal care, nutritional support, mechanical 
ventilation and surfactant are more widely used now than 
in past decades. Given these improvements, the antici-
pated benefits of ACS may therefore not be as large as 
expected. It is noteworthy that infant mortality due to 
respiratory distress syndrome in the USA has decreased 
significantly since the 1970s,32 with large reductions 
achieved prior to the widespread use of ACS.33
Heterogeneity in participants between trials
There is considerable heterogeneity in the eligibility 
criteria used in these trials; table 1 gives the different gesta-
tional age ranges used. Trials have included or excluded 
women with certain obstetric characteristics—women in 
spontaneous preterm labour, women with premature prela-
bour rupture of membranes, women with planned preterm 
birth and women with high-risk obstetric conditions (such 
as multiple pregnancies, diabetes, infection and hyper-
tensive disorders). The pooling of data when trials are so 
diverse may be inappropriate. Furthermore, the preterm 
birth rate after randomisation among women recruited to 
these trials was generally very high. At least 11 trials had 
preterm birth rates at or near 100%, suggesting that these 
trials recruited women who had a very high likelihood of 
delivering preterm. It also raises the possibility that some 
infants exposed to ACS were ultimately born at term, but 
were not captured or included for analysis.
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measurement of neonatal mortality
Twenty-two trials reported on neonatal death; however, none 
were independently powered to detect a difference in this 
outcome. All were facility based, and in general did not specify 
what definition of neonatal death was used, nor how the 
follow-up of newborns to ascertain vital status was conducted. 
Importantly, several trials had excluded women postran-
domisation, some of which may have directly impacted on 
detection of neonatal mortality. In total, this meta-analysis 
included 551 deaths in 6729 newborns (a mortality rate of 
8.2% overall). In low-resource countries, newborn mortality 
rates in preterm newborns can be two to three times higher.
Only seven trials had ≥200 newborns each, accounting 
for 78% of the total sample size for this outcome. The ALPS 
Trial, by far the largest trial for this outcome, reported two 
deaths in the intervention arm and zero in the control 
arm (a non-significant difference). None of the six largest 
trials independently reported a reduction in the risk of 
neonatal death. The seventh (Amorim et al) randomised 
218 pregnant women and reported a 50% risk reduction 
in neonatal death (RR 0.50, 95% CI 0.28 to 0.89); however, 
this trial included only women with severe pre-eclampsia.34 
The remaining 15 trials were all small (<200 newborns 
each); three trials had <100 newborns. Only four small trials 
reported independent reductions in the risk of newborn 
mortality, with effect sizes exceeding 50%.29 35–37 The 
impact of a large number of small trials on the summary 
estimate is of concern. The funnel plot for this outcome 
does not indicate an obvious publication bias, but this does 
not rule out the possibility.38
tHe AntenAtAl CortiCosteroids triAl
In 2015, Althabe and colleagues published findings from 
The Antenatal Corticosteroids Trial (ACT). ACT was a 
community-based, cluster-randomised trial conducted in 
six LMICs: Argentina, Guatemala, India, Kenya, Pakistan 
and Zambia.39 The trial aimed to evaluate the feasibility, 
effectiveness and safety of a multifaceted interven-
tion designed to increase the use of ACS at all levels of 
healthcare. The intervention included ACS commodity 
procurement, as well as training and tools for health 
providers to recognise at-risk women, estimate gesta-
tional age and administer dexamethasone. The primary 
outcome was neonatal death at 28 completed days among 
liveborn neonates at less than fifth percentile for birth 
weight (as a proxy for preterm births, because of inade-
quate gestational age information).
ACT included 101 clusters in six countries, capturing 
nearly 100 000 live births. The use of ACS increased in 
the intervention arm for women with a less-than-fifth-
percentile infant (45% vs 10%), but also for all women, 
regardless of her baby’s birth weight (12% vs 2%). Only 
16% of the women who were given ACS ultimately gave 
birth to a less-than-fifth-percentile newborn, highlighting 
substantial overdiagnosis of imminent preterm birth and 
overtreatment with ACS. Among the less-than-fifth-per-
centile newborns, ACS use had no effect on neonatal 
deaths (RR 0.96, 95% CI 0.87 to 1.06). However, among 
all births, there were increased risks of neonatal mortality 
(RR 1.12, 1.02–1.22) and stillbirth (RR 1.11, 1.02–
1.22)—a very unexpected and concerning finding. The 
authors reported that the increased mortality was seem-
ingly driven by increased mortality in infants above the 
25th percentile for birth weight. Furthermore, the inter-
vention was associated with an increased OR of suspected 
maternal infection in women with less-than-fifth-percen-
tile babies (OR 1.67, 95% CI 1.33 to 2.09), and all women 
(OR 1.45, 95% CI 1.33 to 1.58).
Table 1 Gestational age ranges used in eligibility criteria 
for antenatal corticosteroids administration, reproduced 
with permission from updated Cochrane review24
Study Gestational age range
Amorim 1999 28 weeks 0 days to 34 weeks 6 days
Attawattanakul 
2015
34 weeks 0 days to 36 weeks 6 days
Balci 2010 34 weeks 0 days to 36 weeks 6 days
Block 1977 Up to 36 weeks 6 days*
Cararach 1991 28 weeks 0 days to 30 weeks 6 days
Carlan 1991 28 weeks 0 days to 30 weeks 6 days
Collaborative 
1981
26 weeks 0 days to 37 weeks 0 days
Dexiprom 1999 28 weeks 0 days to 34 weeks 6 days
(or estimated fetal weight 1000–2000 g)
Doran 1980 24 weeks 0 days to 34 weeks 6 days
Fekih 2002 26 weeks 0 days to 34 weeks 6 weeks
Gamsu 1989 Up to 34 weeks 6 days*
Garite 1992 24 weeks 0 days to 27 weeks 6 days
Goodner 1979 Up to 33 weeks 6 days*
Gyamfi-
Bannerman 2016
34 weeks 0 days to 36 weeks 6 days
Kari 1994 24 weeks 0 days to 31 weeks 6 days
Lewis 1996 24 weeks 0 days to 34 weeks 6 days
Liggins 1972 24 weeks 0 days to 36 weeks 6 days
Lopez 1989 27 weeks 0 days to 35 weeks 0 days
Mansouri 2010 25 weeks 0 days to 36 weeks 6 days
Morales 1989 26 weeks 0 days to 34 weeks 6 days
Nelson 1985 28 weeks 0 days to 34 weeks 6 days
Parsons 1988 25 weeks 0 days to 32 weeks 6 days
Porto 2011 34 weeks 0 days to 36 weeks 6 days
Qublan 2001 27 weeks 0 days to 34 weeks 6 days
Schutte 1980 26 weeks 0 days to 32 weeks 6 days
Shanks 2010 34 weeks 0 days to 36 weeks 6 days
Silver 1996 24 weeks 0 days to 29 weeks 6 days
Taeusch 1979 Up to 33 weeks 6 days*
Teramo 1980 28 weeks 0 days to 35 weeks 6 days
*Lower gestational age limit not specified.
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While this complex intervention successfully increased 
the use of ACS more than fourfold in low-resource 
settings, the overall picture was alarming—lack of benefit 
in the less-than-fifth-percentile newborns, evidence of 
increased perinatal mortality in larger newborns and 
the increase in suspected maternal infections. While the 
exact causes are not known, the study group hypothesise 
that maternal and newborn infections may play a role.40
WHo reCommendAtions on use of ACs (2015)
How then should these two contrasting bodies of 
evidence—30 randomized controlled trials largely from 
high-resourced hospitals in higher-income countries, 
and a large implementation trial in six LMICs—be 
balanced? The WHO recommendations on interventions 
to improve preterm birth outcomes were published in 
2015, for which an updated search and meta-analysis was 
conducted.41 WHO recommends ACS for women at risk 
of preterm birth from 24 weeks to 34 weeks gestation in 
settings where certain criteria are met (box 2).42 These 
consensus-based treatment criteria were intended to 
address the issues regarding safety of ACS in resource-lim-
ited settings. The recommendation remarks specify that 
ACS should not be routinely administered in situations 
where the gestational age cannot be confirmed (partic-
ularly when gestational age is suspected to be more than 
34 weeks), as the risk of neonatal harm may outweigh the 
benefits.
The ACT Trial highlighted that scaling up ACS in 
LMICs without more definitive evidence on benefits and 
harms could prove detrimental to both mothers and 
newborns. Given the uncertainties inherent in general-
ising the current evidence base to facilities in low-resource 
settings, and the risk of harm at higher gestational 
ages, the WHO guideline panel recommended further 
research to inform ACS use and improve generalisability 
to lower-resource settings.41
tHe AntenAtAl lAte preterm steroids triAl
The findings of the Antenatal Late Preterm Steroids 
(ALPS) Trial were published in early 2016 (after the 
release of the WHO recommendations).31 This was a 
multicentre, randomised trial in tertiary care centres in 
the USA that recruited women with a singleton preg-
nancy, at high risk for preterm birth and at 34 weeks 0 
days to 36 weeks 5 days of gestation. Participants were 
randomised to receive up to two injections of betameth-
asone or matching placebo, 24 hours apart. The primary 
outcome was a management-based, composite severe 
adverse neonatal outcome relating to need for respiratory 
support. It was defined as one or more of the use of CPAP 
or high-flow nasal cannula for at least two consecutive 
hours, supplemental oxygen with a fraction of inspired 
oxygen of at least 0.30 for at least four continuous hours, 
extracorporeal membrane oxygenation or mechanical 
ventilation. Stillbirth and neonatal death within 72 hours 
were included as competing events.
The authors reported that the primary outcome was 
significantly reduced in the intervention arm, 11.6% vs 
14.4% (RR 0.80; 95% CI 0.66 to 0.97). Other newborn 
secondary outcomes (including severe respiratory 
complications, transient tachypnoea of the newborn, 
surfactant use and bronchopulmonary dysplasia) were 
also significantly less frequent in the betamethasone 
group, although neonatal hypoglycaemia was more 
common in the betamethasone group (24.0% vs 15.0%; 
RR 1.60; 95% CI 1.37 to 1.87). There were no apparent 
differences in the incidence of chorioamnionitis, respira-
tory distress syndrome or neonatal sepsis.
The ALPS Trial findings were meta-analysed with 
similar trials in a recent systematic review by Saccone 
and Berghella, who explored the role of ACS in term 
or near-term fetuses.26 The review included six trials, 
comprising 5698 singleton pregnancies. The review 
authors concluded that ACS at ≥34 weeks’ gestation 
reduces neonatal respiratory morbidity, and that a single 
course of corticosteroids can be considered for women at 
risk of imminent late premature birth (34 weeks 0 days 
to 36 weeks 6 days) gestation, as well as for the subgroup 
of women undergoing planned caesarean delivery at ≥37 
weeks’ gestation.
WHO does not currently recommend the use of ACS 
in the late preterm period, given the lack of evidence 
Box 1 neonatal outcomes of antenatal corticosteroids for 
accelerating fetal lung maturation from updated Cochrane 
review27
 ► 32% reduction in neonatal deaths (Risk Ratio (RR) 0.69, 95% CI 
0.59 to 0.81; 22 studies of 7188 participants)
 ► 35% reduction in respiratory distress syndrome (RDS) (average RR 
0.66, 95% CI 0.56 to 0.77; 28 studies of 7764 participants)
 ► 45% reduction in moderate and severe RDS (average RR 0.59, 
95% CI 0.38 to 0.91; 6 studies of 1686 participants)
 ► 46% reduction in intraventricular haemorrhage (average RR 0.55, 
95% CI 0.40 to 0.76; 16 studies of 6093 participants)
 ► 54% reduction in necrotising enterocolitis (RR 0.50, 95% CI 0.32 to 
0.78; 10 studies of 4702 participants)
 ► 43% reduction in infant systemic infection in the first 48 hours of 
life (RR 0.60, 95% CI 0.41 to 0.88; 8 studies of 1753 participants)
Box 2 Antenatal corticosteroids treatment criteria in 
the WHo recommendations to improve preterm birth 
outcomes42
 ► Gestational age assessment can be accurately undertaken
 ► Preterm birth is considered imminent
 ► There is no clinical evidence of maternal infection
 ► Adequate childbirth care is available (including the capacity to 
recognise and safely manage preterm labour and birth)
 ► The preterm newborn can receive adequate care if needed 
(including resuscitation, thermal care, feeding support, infection 
treatment and safe oxygen use)
Vogel JP, et al. BMJ Glob Health 2017;2:e000398. doi:10.1136/bmjgh-2017-000398 5
BMJ Global Health
of benefit at the time the WHO recommendations 
were developed. While the findings of the ALPS Trial 
suggest that ACS in the late preterm period could reduce 
newborn respiratory morbidity (but not fetal or neonatal 
mortality) in high-resource settings, it is not certain that 
these findings—which relate largely to reducing the need 
for newborn care interventions available in high-level 
hospitals—can be replicated in hospitals in LMICs where 
considerably fewer health and human resources are avail-
able. Late preterm ACS use might confer a mortality 
benefit in low-resource settings, where rates of neonatal 
mortality in late preterm newborns are unacceptably 
high, but this is speculative.
tHe CAse for equipoise, And tHe need for effiCACy 
triAls in loW-resourCe settings
In November 2015, WHO convened a technical consul-
tation of obstetricians, neonatologists and researchers 
in preterm birth to review and discuss the knowledge 
gaps around ACS use prior to 34 weeks. With the publi-
cation of the ALPS Trial in February 2016, an additional 
meeting of researchers and technical advisors was held in 
July 2016 to review the evidence around the late preterm 
period.
Based on the evidence appraisal above, it was agreed 
that there is a clear justification for further randomised 
controlled trials to evaluate the efficacy of ACS in facility 
settings in lower-income countries. While evidence 
suggests that there may be a role for ACS in preterm 
birth management in these settings, efficacy evidence 
from hospitals in low-resource countries that balances 
possible maternal, fetal and neonatal benefits and harms 
is required to guide clinical practice.
The group noted that if the conduct of such an effi-
cacy trial is limited to women at imminent risk of early 
preterm birth (<34 weeks), future recommendations on 
ACS use would continue to be restricted to this gesta-
tional age limit. This can complicate ACS scale-up in 
most low-resource countries, where accurate gestational 
age assessment is often not available. The outstanding 
question of possible benefits and harms for mothers and 
late preterm babies will also remain unresolved.
If a separate, independently powered efficacy trial of 
ACS in the late preterm period showed benefit, the public 
health impact will be significant. Compared with early 
preterm births, neonatal mortality rates are lower in late 
preterm babies, but the prevalence is more than three 
times larger. Even modest benefits (in the absence of 
harms) would thus translate into substantive impacts on 
preterm-associated morbidity, mortality and healthcare 
utilisation. If neither benefits nor harms are demon-
strated in the late preterm period, reliance on accurate 
gestational age assessment around 34 weeks will be less 
critical. The various scenarios are summarised in table 2.
This has led to the establishment of an international 
research collaboration, called the WHO Antenatal 
CorticosTeroids for Improving Outcomes in preterm 
Newborns (WHO ACTION) Trials. With support from 
the Bill and Melinda Gates Foundation, this collabora-
tion will conduct two concurrent and independently 
powered, hospital-based, placebo-controlled efficacy 
trials of ACS (dexamethasone), which will recruit women 
presenting to participating hospitals at imminent risk 
of preterm birth. The ACTION-I trial will randomise 
eligible women from 26 weeks 0 days to 33 weeks 6 days, 
while the ACTION-II trial will randomise eligible women 
from 34 weeks 0 days to 36 weeks 0 days. The trials will be 
conducted in hospitals with a sufficient level of maternal 
and newborn care in Bangladesh, India, Kenya, Nigeria 
and Pakistan. These hospitals will be supported (where 
necessary) with additional equipment and training, in 
order to optimise gestational age dating, as well as care 
of preterm newborns. When concluded, these two trials 
will add more than 28 000 women to the Cochrane review 
meta-analysis on this question, providing the needed trial 
evidence on ACS use in low-resource countries.
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